HRA006345
Title:
Precision Induction Therapy for Inoperable NSCLC in Stage III Disease: A Phase II Umbrella Clinical Trial
Release date:
2025-01-26
Description:
The objective is to assess the efficacy and safety of precision induction therapies in patients with unresectable stage III NSCLC selected based on tumor PD-L1 expression. Patients were stratified into groups receiving Sintilimab monotherapy, Sintilimab plus IBI305, or Sintilimab combined with chemotherapy. Multi-disciplinary team (MDT) to discuss whether surgery was performed 3-4 weeks after last dose of therapy. Surgery was performed 4-6 weeks after last dose of induction therapy. RNA-seq and WES were performed at baseline, and the tumor samples were also collected for RNA-seq after surgery. Based on bioinformatics analysis, we want to find better biomarker to stratified patients and explore optimized regimens for unresectable stage III NSCLC.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
non-small cell lung carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
LungMate-017
Contact person:
Zhang Peng
Email:
zhangpeng1121@tongji.edu.cn
Description:
The objective is to assess the efficacy and safety of precision induction therapies in patients with unresectable stage III NSCLC selected based on tumor PD-L1 expression. Patients were stratified into groups receiving Sintilimab monotherapy, Sintilimab plus IBI305, or Sintilimab combined with chemotherapy. Multi-disciplinary team (MDT) to discuss whether surgery was performed 3-4 weeks after last dose of therapy. Surgery was performed 4-6 weeks after last dose of induction therapy. This data set includes RNA-seq and WES data. The tissue collected from baseline patietns were send for RNA-seq and WES, and the tumor samples collected after surgery were send for RNA-seq only.
Individuals & samples
Submitter:   Zhang Peng / zhangpeng1121@tongji.edu.cn
Organization:   Shanghai Pulmonary Hospital Tongji University
Submission date:   2023-12-04
Requests:   4